AIMS: To investigate impacts of withdrawal and regulatory advice regarding cyclooxygenase-2 (COX-2) inhibitors on UK population rates of gastrointestinal haemorrhage and acute myocardial infarction (MI). METHODS: Ecological time series study of prescribing, mortality and hospital admission trends in people aged > or = 55 years. RESULTS: Withdrawal and regulatory advice limiting COX-2 inhibitor availability from 2004 were temporally associated with reversal of previously unfavourable trends in emergency MI admissions among people aged > or = 65 years. Annual admission rate trends changed from +4.6% to -3.1% (P < 0.001) among women and from +2.1% to -3.8% (P= 0.003) among men. Absolute changes in average annual trend in the number of individuals aged > or = 65 years admitted following MI were from +981 (1999-2004) to -819 (2004-2006) per year for women and from +713 to -995 for men. No change in trend was apparent among people aged 55-64 years, or in MI mortality trends. There was some suggestion of an unfavourable change in admission trends for gastrointestinal haemorrhage among 55-64-year-olds, although this appeared to occur prior to COX-2 inhibitor withdrawal/regulation by up to 2 years. These trends were not apparent in older people, or in gastrointestinal haemorrhage mortality rates. CONCLUSIONS: Withdrawal/regulation of COX-2 inhibitors was temporally associated with a favourable reversal of population-level hospital admission trends in MI among people aged > or = 65 years. Unfavourable reversal of previous declines in gastrointestinal haemorrhage admissions probably occurred before changes in COX-2 inhibitor availability. Withdrawal/ regulation of COX-2 inhibitors did not appear to have any adverse impact on population health and may have been beneficial.
AIMS: To investigate impacts of withdrawal and regulatory advice regarding cyclooxygenase-2 (COX-2) inhibitors on UK population rates of gastrointestinal haemorrhage and acute myocardial infarction (MI). METHODS: Ecological time series study of prescribing, mortality and hospital admission trends in people aged > or = 55 years. RESULTS: Withdrawal and regulatory advice limiting COX-2 inhibitor availability from 2004 were temporally associated with reversal of previously unfavourable trends in emergency MI admissions among people aged > or = 65 years. Annual admission rate trends changed from +4.6% to -3.1% (P < 0.001) among women and from +2.1% to -3.8% (P= 0.003) among men. Absolute changes in average annual trend in the number of individuals aged > or = 65 years admitted following MI were from +981 (1999-2004) to -819 (2004-2006) per year for women and from +713 to -995 for men. No change in trend was apparent among people aged 55-64 years, or in MI mortality trends. There was some suggestion of an unfavourable change in admission trends for gastrointestinal haemorrhage among 55-64-year-olds, although this appeared to occur prior to COX-2 inhibitor withdrawal/regulation by up to 2 years. These trends were not apparent in older people, or in gastrointestinal haemorrhage mortality rates. CONCLUSIONS: Withdrawal/regulation of COX-2 inhibitors was temporally associated with a favourable reversal of population-level hospital admission trends in MI among people aged > or = 65 years. Unfavourable reversal of previous declines in gastrointestinal haemorrhage admissions probably occurred before changes in COX-2 inhibitor availability. Withdrawal/ regulation of COX-2 inhibitors did not appear to have any adverse impact on population health and may have been beneficial.
Authors: S Capewell; B M Livingston; K MacIntyre; J W Chalmers; J Boyd; A Finlayson; A Redpath; J P Pell; C J Evans; J J McMurray Journal: Eur Heart J Date: 2000-11 Impact factor: 29.983
Authors: F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis Journal: JAMA Date: 2000-09-13 Impact factor: 56.272
Authors: D M Livermore; P Stephens; J Weinberg; A P Johnson; T Gifford; D Northcott; D James; R C George; D C Speller Journal: J Antimicrob Chemother Date: 2000-09 Impact factor: 5.790
Authors: C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer Journal: N Engl J Med Date: 2000-11-23 Impact factor: 91.245
Authors: Sigrid Piening; Flora M Haaijer-Ruskamp; Jonie T N de Vries; Menno E van der Elst; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol Journal: Drug Saf Date: 2012-05-01 Impact factor: 5.606
Authors: Margaret A Gates; Andre B Araujo; Susan A Hall; Gary A Wittert; John B McKinlay Journal: Clin Endocrinol (Oxf) Date: 2012-02 Impact factor: 3.478
Authors: John Bian; Brian Chen; Dawn L Hershman; Norman Marks; LeAnn Norris; Richard Schulz; Charles L Bennett Journal: J Clin Oncol Date: 2017-04-25 Impact factor: 44.544
Authors: Margaret A Gates; Susan A Hall; Gretchen R Chiu; Varant Kupelian; Mary P Fitzgerald; Carol L Link; John B McKinlay Journal: Am J Epidemiol Date: 2011-02-28 Impact factor: 4.897